AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 255
- Registration Number
- NCT00235950
- Locations
- 🇸🇪
Research Site, Örebro, Sweden
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2011-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 490
- Registration Number
- NCT00234468
- Locations
- 🇮🇹
Research Site, Venezia-Mestre, Italy
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT00234442
- Locations
- 🇮🇹
Research Site, Rozzano, Italy
IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00234416
- Locations
- 🇪🇸
Research Site, Valencia, Spain
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00234403
- Locations
- 🇪🇸
Investigative Site, Zaragoza, Spain
Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 550
- Registration Number
- NCT00234377
- Locations
- 🇭🇺
Research Site, Szekesfehervar, Hungary
PreAsthmaControl (PAC)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00234390
- Locations
- 🇩🇰
Research Site, Copenhagen, Denmark
A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 74
- Registration Number
- NCT00234429
- Locations
- 🇪🇸
Research Site, Valladolid, Spain
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT00233636
- Locations
- 🇮🇹
Research Site, Ragusa, Italy
Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT00233623
- Locations
- 🇮🇹
Research Center, Bari, Italy
🇮🇹Research Site, Venezia, Italy
© Copyright 2024. All Rights Reserved by MedPath